When used in conjunction with anti-PD-1 therapy, CXCL13 effectively hindered tumor growth by enhancing the influx of cytotoxic CD8+ T cells and promoting the maintenance of CXCR5+ CD8+ T-cells within tertiary lymphoid structures (TLS). Here, PDCD1 is linked to neoplasm.